论文部分内容阅读
目的探讨分析大剂量厄贝沙坦治疗慢性肾脏病患者临床蛋白尿的疗效。方法 120例慢性肾脏病患者,按照治疗方法的不同将其分为大剂量组及小剂量组,每组60例。小剂量组给予150 mg/d厄贝沙坦治疗,大剂量组给予300 mg/d厄贝沙坦治疗。比较两组患者治疗前后血压、24 h尿蛋白定量以及血肾功能变化情况。结果治疗后,大剂量组患者收缩压、舒张压均低于对照组,差异具有统计学意义(P<0.05)。治疗后,大剂量组患者24 h尿蛋白定量为(1.66±0.57)g/24 h,低于小剂量组的(2.12±0.72)g/24 h,差异具有统计学意义(P<0.05)。治疗后大剂量组患者尿素氮、血肌酐低于对照组,肾小球滤过率(GFR)高于对照组,差异具有统计学意义(P<0.05)。结论大剂量厄贝沙坦治疗慢性肾脏病患者疗效显著,可有效的减轻患者的症状,降低其蛋白尿,值得临床推广应用。
Objective To investigate the clinical efficacy of high-dose irbesartan in the treatment of clinical proteinuria in patients with chronic kidney disease. Methods 120 cases of chronic kidney disease patients were divided into high dose group and low dose group according to the different treatment methods, each group of 60 cases. Low-dose group was given irbesartan 150 mg / d, high-dose group was given irbesartan 300 mg / d. Blood pressure, 24 h urinary protein and blood renal function were compared between the two groups before and after treatment. Results After treatment, systolic blood pressure and diastolic blood pressure were lower in the high-dose group than those in the control group, with statistical significance (P <0.05). After treatment, 24 h urinary protein in high-dose group was (1.66 ± 0.57) g / 24 h, lower than that in low-dose group (2.12 ± 0.72) g / 24 h, the difference was statistically significant (P <0.05). After treatment, the levels of urea nitrogen and serum creatinine in the high-dose group were lower than those in the control group, and the glomerular filtration rate (GFR) was higher than that in the control group. The difference was statistically significant (P <0.05). Conclusion High-dose irbesartan treatment of chronic kidney disease patients with significant effect, which can effectively reduce the symptoms and reduce its proteinuria, deserved clinical application.